11.01.07
Indication: Generalized anxiety disorder
Source: J Psychiatr Res, September 2007;41(6):472-80.
Research: Researchers from Germany conducted a study with 107 patients with generalized anxiety disorder (82 patients) or adjustment disorder with anxious mood (25 patients), according to the diagnostic and statistical manual of mental disorders. The patients were randomized to receive daily doses of 480 mg EGb 761, 240 mg EGb 761 or placebo for four weeks. Intention-to-treat (ITT) analyses were performed on the primary outcome measure, the Hamilton rating scale for anxiety, the secondary variables, the clinical global impression of change (CGI-C), the Erlangen anxiety tension and aggression scale (EAAS), the list of complaints, and the patient's global rating of change.
Results: The Hamilton rating scale for anxiety total scores decreased by -14.3, -12.1 and -7.8 in the high-dose EGb 761, the low-dose EGb 761 and the placebo group, respectively. Changes were considered significantly different from placebo for both treatment groups. Regression analyses revealed a dose-response trend. The study authors concluded that EGb 761 was significantly superior to placebo on all secondary outcome measures. Because it was safe and well tolerated, researchers believe it may be of particular value in elderly patients with anxiety related to cognitive decline.
Source: J Psychiatr Res, September 2007;41(6):472-80.
Research: Researchers from Germany conducted a study with 107 patients with generalized anxiety disorder (82 patients) or adjustment disorder with anxious mood (25 patients), according to the diagnostic and statistical manual of mental disorders. The patients were randomized to receive daily doses of 480 mg EGb 761, 240 mg EGb 761 or placebo for four weeks. Intention-to-treat (ITT) analyses were performed on the primary outcome measure, the Hamilton rating scale for anxiety, the secondary variables, the clinical global impression of change (CGI-C), the Erlangen anxiety tension and aggression scale (EAAS), the list of complaints, and the patient's global rating of change.
Results: The Hamilton rating scale for anxiety total scores decreased by -14.3, -12.1 and -7.8 in the high-dose EGb 761, the low-dose EGb 761 and the placebo group, respectively. Changes were considered significantly different from placebo for both treatment groups. Regression analyses revealed a dose-response trend. The study authors concluded that EGb 761 was significantly superior to placebo on all secondary outcome measures. Because it was safe and well tolerated, researchers believe it may be of particular value in elderly patients with anxiety related to cognitive decline.